Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Victor G VogelThe University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USAAbstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolis...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Victor G Vogel
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	raloxifene osteoporosis breast cancer risk reduction Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/1e041e0247bf4427836baa6118c6155e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1e041e0247bf4427836baa6118c6155e
record_format	dspace
spelling	oai:doaj.org-article:1e041e0247bf4427836baa6118c6155e2021-12-02T05:00:16ZManaging the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene1178-1998https://doaj.org/article/1e041e0247bf4427836baa6118c6155e2008-12-01T00:00:00Zhttps://www.dovepress.com/managing-the-risk-of-invasive-breast-cancer-in-women-at-risk-for-breas-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Victor G VogelThe University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USAAbstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease risk, but it has no significant effect on the risk of primary coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% confidence interval [CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer.Keywords: raloxifene, osteoporosis, breast cancer risk reductionVictor G VogelDove Medical Pressarticleraloxifeneosteoporosisbreast cancer risk reductionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 601-609 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	raloxifene osteoporosis breast cancer risk reduction Geriatrics RC952-954.6
spellingShingle	raloxifene osteoporosis breast cancer risk reduction Geriatrics RC952-954.6 Victor G Vogel Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
description	Victor G VogelThe University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA, USAAbstract: Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) that has antiestrogenic effects on breast and endometrial tissue and estrogenic effects on bone, lipid metabolism, and blood clotting. Raloxifene significantly improves serum lipids and serum markers of cardiovascular disease risk, but it has no significant effect on the risk of primary coronary events. A meta-analysis of randomized, double-blind, placebo-controlled trials of raloxifene for osteoporosis showed the odds of fracture risk were 0.60 (95% confidence interval [CI] = 0.49–0.74) for raloxifene 60 mg/day compared with placebo. During 8 years of follow-up in an osteoporosis trial, the raloxifene group had a 76% reduction in the incidence of invasive ER-positive breast cancer compared with the placebo group. In the STAR trial, the incidence of invasive breast cancer was 4.30 per 1000 women-years with raloxifene and 4.41 per 1000 with tamoxifen; RR = 1.02; 95% CI, 0.82–1.28. The effect of raloxifene on invasive breast cancer was, therefore, equivalent to that of tamoxifen with more favorable rates of adverse effects including uterine malignancy and clotting events. Millions of postmenopausal women could derive net benefit from raloxifene through reduced rates of fracture and invasive breast cancer.Keywords: raloxifene, osteoporosis, breast cancer risk reduction
format	article
author	Victor G Vogel
author_facet	Victor G Vogel
author_sort	Victor G Vogel
title	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
title_short	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
title_full	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
title_fullStr	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
title_full_unstemmed	Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
title_sort	managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1e041e0247bf4427836baa6118c6155e
work_keys_str_mv	AT victorgvogel managingtheriskofinvasivebreastcancerinwomenatriskforbreastcancerandosteoporosistheroleofraloxifene
_version_	1718400816267657216

Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene

Ejemplares similares